Abstract: In an AMFC, in the formation of a CCM, the anode catalyst layer is selectively cross-linked while the cathode catalyst layer is not cross-linked. This has been found to provide structural stabilization of the CCM without loss of initial power value for a CCM without cross-linking.
Abstract: The invention provides expression vectors containing the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus. Further vectors including the hCMV-MIE DNA linked directly to the coding sequence of a heterologous gene are described, Host cells transfected with the vectors and a process for producing heterologous polypeptides using the vectors and the use of the hCMV-MIE DNA for expression of a heterologous gene are also included within the invention.
Abstract: A process for the production of a fusion protein comprising an active portion of a chloramphenicol acetyltransferase (CAT) protein and a polypeptide. The fusion protein may be purified using CAT substrate affinity chromatography. The eucaryotic polypeptide may be calcitonin or a dervative thereof such as calcitonin-glycine. Other polypeptides described include enzymes such as chymosin, prochymosin and preprochymosin, hormones such as ACTH, insulins, and growth hormones and antigenic polypetides such as foot and mouth disease virus antigenic polypetide. The fusion protein may be cleaved at a site susceptible to selective enzymic or chemical cleavage to produce free polypeptide. The fusion protein may be used as an immunogen.
Type:
Grant
Filed:
September 23, 1988
Date of Patent:
March 3, 1992
Assignee:
Celltech, Ltd.
Inventors:
Alan D. Bennett, Stephen K. Rhind, Peter A. Lowe, Christopher C. G. Hentschel